辫丑辞蝉辫丑辞-肠-搁补蹿(厂别谤338/罢测谤340)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产物编号xy- 1731R
英文名称辫丑辞蝉辫丑辞-肠-搁补蹿(厂别谤338/罢测谤340)
中文名称磷酸化原癌基因肠-搁补蹿抗体
别 名p-Raf-1(Ser338/Tyr340);RAF1; murine leukemia viral (v-raf-1) oncogene homolog 1 (3611-MSV); v-raf-1 murine leukemia viral oncogene homolog 1; cRaf; C-RAF; proto-oncogene c-RAF; 6430402F14Rik; AA990557; BB129353; c-Raf; Craf1; D830050J10Rik; MGC102375; Raf-1; Raf 1; v-Raf; c Raf; Craf 1 transforming gene; Craf1 transforming gene; EC 2.7.11.1; Murine sarcoma 3611 oncogene 1; RAF; Raf proto oncogene serine/threonine protein kinase; vraf1 murine leukemia viral oncogene homolog 1.
说 明 书100ul
产物类型磷酸化抗体
研究领域肿瘤 细胞生物 染色质和核信号 神经生物学 信号转导 细胞凋亡 细胞周期蛋白 转录调节因子 激酶和磷酸酶 细胞分化 线粒体
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
辫丑辞蝉辫丑辞-肠-搁补蹿(厂别谤338/罢测谤340)抗体交叉反应 Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, Guinea Pig,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量73kDa
细胞定位细胞核 细胞浆 细胞膜 线粒体
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human c-Raf around the phosphorylation site of Ser338/Tyr340:RD(p-S)S(p-Y)YW
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
辫丑辞蝉辫丑辞-肠-搁补蹿(厂别谤338/罢测谤340)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
The Raf family of serine/threonine specific kinases is comprised of three members (aRaf, bRaf, and cRaf) that play a critical role in regulating cell growth and differentiation, and couple growth factor receptor stimulation to nuclear transcription factors via the Ras/mitogen activated protein kinase (MAPK) pathway. cRaf kinase (also known as Raf1) is a small GTPase like kinase of 73 kDa, and is a signal transducer of multiple extracellular stimuli that is regulated by several pathways, and that once activated, phosphorylates MEK which in turn phosphorylates ERK. Raf1 is involved in the transduction of mitogenic signals from the cell membrane to the nucleus. It is part of the Ras dependent signaling pathway from receptors to the nucleus.
Function:
Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation. [CATALYTIC ACTIVITY] ATP + a protein = ADP + a phosphoprotein.
Subunit:
Monomer. Homodimer. Heterodimerizes with BRAF and this heterodimer possesses a highly increased kinase activity compared to the respective homodimers or monomers. Heterodimerization is mitogen-regulated and enhanced by 14-3-3 proteins. MAPK1/ERK2 activation can induce a negative feedback that promotes the dissociation of the heterodimer. Forms a multiprotein complex with Ras (M-Ras/MRAS), SHOC2 and protein phosphatase 1 (PPP1CA, PPP1CB and PPP1CC). Interacts with Ras proteins; the interaction is antagonized by RIN1. Weakly interacts with RIT1. Interacts (via N-terminus) with RGS14 (via RBD domains); the interaction mediates the formation of a ternary complex with BRAF, a ternary complex inhibited by GNAI1 (By similarity). Interacts with STK3/MST2; the interaction inhibits its pro-apoptotic activity. Interacts (when phosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-232'). Interacts with MAP2K1/MEK1 and MAP2K2/MEK2 (By similarity). Interacts with MAP3K5/ASF1 (via N-terminus) and this interaction inhibits the proapoptotic function of MAP3K5/ASK1. Interacts with PAK1 (via kinase domain). The phosphorylated form interacts with PIN1. The Ser-338 and Ser-339 phosphorylated form (by PAK1) interacts with BCL2. Interacts with PEBP1/ and this interaction is enhanced if RAF1 is phosphorylated on residues Ser-338, Ser-339, Tyr-340 and Tyr-341. Interacts with ADCY2, ADCY5, ADCY6, DGKH, RCAN1/DSCR1, ROCK2, PPP1R12A, PKB/AKT1, PPP2CA, PPP2R1B, SPRY2, SPRY4, CNKSR1/CNK1, KSR2 and PHB/prohibitin.
Subcellular Location:
Cytoplasm. Cell membrane. Mitochondrion. Nucleus. Note=Colocalizes with RGS14 and BRAF in both the cytoplasm and membranes. Phosphorylation at Ser-259 impairs its membrane accumulation. Recruited to the cell membrane by the active Ras protein. Phosphorylation at Ser-338 and Ser-339 by PAK1 is required for its mitochondrial localization. Retinoic acid-induced Ser-621 phosphorylated form of RAF1 is predominantly localized at the nucleus.
Tissue Specificity:
In skeletal muscle, isoform 1 is more abundant than isoform 2. [PTM] Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylation at Thr-269, Ser-338, Tyr-341, Thr-491 and Ser-494 results in its activation. Phosphorylation at Ser-29, Ser-43, Ser-289, Ser-296, Ser-301 and Ser-642 by MAPK1/ERK2 results in its inactivation. Phosphorylation at Ser-259 induces the interaction with YWHAZ and inactivates kinase activity. Dephosphorylation of Ser-259 by the complex containing protein phosphatase 1, SHOC2 and M-Ras/MRAS relieves inactivation, leading to stimulate RAF1 activity. Phosphorylation at Ser-338 by PAK1 and PAK7/PAK5 and Ser-339 by PAK1 is required for its mitochondrial localization.
DISEASE:
Defects in RAF1 are the cause of Noonan syndrome type 5 (NS5) [MIM:611553]. Noonan syndrome (NS) is a disorder characterized by dysmorphic facial features, short stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a bleeding diathesis. It is a genetically heterogeneous and relatively common syndrome, with an estimated incidence of 1 in 1000-2500 live births.
Defects in RAF1 are the cause of LEOPARD syndrome type 2 (LEOPARD2) [MIM:611554]. LEOPARD syndrome is an autosomal dominant disorder allelic with Noonan syndrome. The acronym LEOPARD stands for lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and deafness.
Similarity:
Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. RAF subfamily.
Contains 1 phorbol-ester/DAG-type zinc finger.
Contains 1 protein kinase domain.
Contains 1 RBD (Ras-binding) domain.
SWISS:
P04049
Gene ID:
5894
辫丑辞蝉辫丑辞-肠-搁补蹿(厂别谤338/罢测谤340)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“驰”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
辫丑辞蝉辫丑辞-肠-搁补蹿(厂别谤338/罢测谤340)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 Gemin 7 脊髓性肌萎缩症蛋白Gemin7抗体
合格 合格 phospho-GFAP (Ser38) 磷酸化胶质纤维酸性蛋白抗体
合格 GFI1 自主生长因子GFI1抗体
合格 合格 G 延伸因子G2抗体
合格 GGA2 γ-衔接蛋白相关蛋白2抗体
合格 GGA3 γ-衔接蛋白相关蛋白3抗体
合格 GGN 配子生成素抗体
合格 TIE1 血管生成素受体1抗体
合格 合格 Giantin 高尔基体相关蛋白GM130抗体
合格 合格 Notch1 跨膜受体蛋白Notch-1抗体
合格 合格 GJA10 间隙连接蛋白10抗体
合格 GKAP1 G激酶锚定蛋白1抗体
合格 GLT1D1 糖基转移酶1结构域1抗体
合格 GLT25D2 糖基转移酶25结构域2/前胶原半乳糖基转移酶2抗体
合格 Phospho-Glucocorticoid Receptor (Ser226) 磷酸化糖皮质**受体抗体
合格 Fx1A 肾刷状缘抗体
合格 phospho-GluR1 (Thr840) 磷酸化谷氨酸受体1抗体
合格 合格 Glutaredoxin 2 谷氧还蛋白2抗体
合格 GSTA1 谷胱甘肽S转移酶α1抗体
合格 合格 合格 CK18 细胞角蛋白18抗体（C端）
合格 GSTT1 谷胱甘肽S转移酶θ/Glutathione S Transferase theta 1抗体
合格 合格 phospho-AMPK alpha 1 (Ser496) 磷酸化腺苷单磷酸活化蛋白激酶α1抗体
合格 合格 FAK 粘着斑激酶抗体
合格 NRF1 核呼吸因子-1抗体
合格 Ezrin/Radixin 埃兹蛋白抗体
合格 GM2A 神经鞘脂激活蛋白3抗体
合格 Fibronectin/Ugl-Y3 纤维连接蛋白/Ugl-Y3抗体
合格 合格 GMIP GEM相互作用蛋白抗体
合格 PODXL 足细胞特异蛋白抗体
合格 GNB1L G蛋白β样蛋白抗体
合格 GNG13 G蛋白γ13/Gγ13 抗体
合格 GNL2 鸟嘌呤核苷酸结合蛋白2抗体